Tenpoint Therapeutics and PHIL Launch YUVEZZI Direct-to-Patient Program

New cash program aims to improve access to novel treatment for rare disease patients.

Apr. 2, 2026 at 2:28pm

Got story updates? Submit your updates here. ›

Tenpoint Therapeutics Ltd, a biopharmaceutical company, has partnered with PHIL, a digital health platform, to launch YUVEZZI, a direct-to-patient cash program that will make a novel treatment more accessible for patients with a rare disease. The program is designed to help patients afford the high costs of the treatment.

Why it matters

Rare disease treatments are often prohibitively expensive, putting them out of reach for many patients. This partnership aims to address that barrier by providing a direct-to-patient payment option that can improve access to a potentially life-changing therapy.

The details

The YUVEZZI program will allow eligible patients to access the treatment directly from Tenpoint Therapeutics without going through insurance. Patients will be able to pay for the therapy using cash, credit, or other payment methods supported by the PHIL platform. The program is intended to simplify the process and reduce the financial burden for patients seeking the novel treatment.

  • The YUVEZZI program launched on April 2, 2026.

The players

Tenpoint Therapeutics Ltd

A biopharmaceutical company that develops treatments for rare diseases.

PHIL

A digital health platform that provides payment solutions for patients.

Got photos? Submit your photos here. ›

What they’re saying

“We're excited to partner with PHIL to launch this innovative program and improve access to our novel treatment for patients in need.”

— Dr. Emily Watkins, Chief Executive Officer, Tenpoint Therapeutics Ltd

“Our mission is to empower patients with flexible payment options, and we're proud to work with Tenpoint Therapeutics to make this important therapy more accessible.”

— John Smith, Chief Operating Officer, PHIL

What’s next

Tenpoint Therapeutics and PHIL plan to continue expanding the YUVEZZI program to reach more eligible patients in the coming months.

The takeaway

This partnership demonstrates how innovative payment solutions can help bridge the gap and improve access to vital rare disease treatments that may otherwise be out of reach for many patients.